文献速递心脏核医学肿瘤 PET/CT

运动校正[68Ga]戊聚糖苷PET/CT成像急性心肌梗死后罪犯与非罪犯冠状动脉粥样硬化斑块的趋化因子受体CXCR4表达

Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-07-03

研究在37例首次急性ST段抬高型心肌梗死后支架再灌注患者中,采用运动校正的[68Ga]pentixafor PET/CT分析罪犯与非罪犯冠状动脉病变的CXCR4表达。离体证实CXCR4在粥样硬化病变中上调并与CD68+炎症细胞共定位。在体罪犯病变CXCR4信号最强(中位SUVmax 1.96),支架内非罪犯病变(1.45,P=0.048)及 naive 远端冠脉节段热点(1.34,P=0.0005)显著较低。双门控提供最强信号和最高病变可检测性。

要点

  • 运动校正[68Ga]pentixafor PET/CT可评估冠状动脉病变CXCR4表达。
  • 罪犯病变CXCR4信号最强(中位SUVmax 1.96)。
  • 支架内非罪犯病变与 naive 远端热点信号显著较低。

核心结论

  • 研究证实运动校正靶向PET/CT成像冠状动脉病变CXCR4表达的基本可行性,该表达由血管壁炎症及支架所致损伤触发。
  • 作者认为这一新方法可能作为未来针对冠状动脉粥样硬化斑块生物学的诊断和治疗临床研究的平台。

研究设计与样本

  • 研究在37例首次急性ST段抬高型心肌梗死后接受支架再灌注的患者中进行[68Ga]pentixafor PET/CT。
  • 离体分析另行获取的动脉壁标本CXCR4表达。
  • 列表模式PET数据采用心脏和/或呼吸门控重建为五个不同数据集,以CT引导定位,分析并比较罪犯病变与各组非罪犯冠状动脉病变的PET信号。

主要发现

  • 离体显示CXCR4在粥样硬化病变中上调,主要与CD68+炎症细胞共定位。
  • 在体罪犯冠状动脉病变CXCR4 PET信号最强,中位SUVmax 1.96(四分位距IQR 1.55-2.31)。
  • 支架内非罪犯病变中位SUVmax 1.45(IQR 1.23-1.88;P=0.048),显著低于罪犯病变。
  • naive远端冠状动脉节段热点中位SUVmax 1.34(IQR 1.23-1.74;P=0.0005),显著低于罪犯病变。
  • 双心脏/呼吸门控提供最强的CXCR4 PET信号和最高的病变可检测性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The chemokine receptor CXCR4 is a promising target for molecular imaging of CXCR4+ cell types, e.g. inflammatory cells, in cardiovascular diseases. We speculated that a specific CXCR4 ligand, [68Ga]pentixafor, along with novel techniques for motion correction, would facilitate the in vivo characterization of CXCR4 expression in small culprit and nonculprit coronary atherosclerotic lesions after acute myocardial infarction by motion-corrected targeted PET/CT. METHODS: CXCR4 expression was analysed ex vivo in separately obtained arterial wall specimens. [68Ga]Pentixafor PET/CT was performed in 37 patients after stent-based reperfusion for a first acute ST-segment elevation myocardial infarction. List-mode PET data were reconstructed to five different datasets using cardiac and/or respiratory gating. Guided by CT for localization, the PET signals of culprit and various groups of nonculprit coronary lesions were analysed and compared. RESULTS: Ex vivo, CXCR4 was upregulated in atherosclerotic lesions, and mainly colocalized with CD68+ inflammatory cells. In vivo, elevated CXCR4 expression was detected in culprit and nonculprit lesions, and the strongest CXCR4 PET signal (median SUVmax 1.96; interquartile range, IQR, 1.55-2.31) was observed in culprit coronary artery lesions. Stented nonculprit lesions (median SUVmax 1.45, IQR 1.23-1.88; P = 0.048) and hot spots in naive remote coronary segments (median SUVmax 1.34, IQR 1.23-1.74; P = 0.0005) showed significantly lower levels of CXCR4 expression. Dual cardiac/respiratory gating provided the strongest CXCR4 PET signal and the highest lesion detectability. CONCLUSION: We demonstrated the basic feasibility of motion-corrected targeted PET/CT imaging of CXCR4 expression in coronary artery lesions, which was triggered by vessel wall inflammation but also by stent-induced injury. This novel methodology may serve as a platform for future diagnostic and therapeutic clinical studies targeting the biology of coronary atherosclerotic plaque.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Derlin T, Sedding DG, Dutzmann J, et al. Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT. Eur J Nucl Med Mol Imaging. 2018. PMID: 29967943. doi:10.1007/s00259-018-4076-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。